Evidence map›Paper›PMID 39184819›Full record

ReviewInternational journal of molecular and cellular medicine2024

A Review of the Interaction between miRNAs and Ebola Virus.

Ehsan Kakavandi, Jila Yavarian, Mahdieh Farzanehpour, Mohammad Shayestehpour

Abstract readReview
In one paragraph

Review in International journal of molecular and cellular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ehsan KakavandiDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Jila YavarianDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Mahdieh FarzanehpourApplied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mohammad ShayestehpourDepartment of Bacteriology and Virology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ebola virus (EBOV) is a life-threatening and virulent pathogen that kills approximately 90 percent of infected individuals. Nowadays, microRNAs (miRNAs) have become a promising option for more efficient screening, diagnosis, monitoring, and therapy of numerous diseases such as cancer, stroke, Alzheimer's, and viral infections. Recent studies have revealed the role of EBOV and host-encoded miRNAs in Ebola virus disease (EVD), opening an avenue for developing novel drugs against EVD and diagnostic panels for EBOV infection. EBOV-encoded miRNAs such as miR-VP-3p and miR-1-5p and anti-EBOV host cell miRNAs such as has-miR-150-3p, has-miR-103b and has-miR-145-3p might be a possible diagnostic biomarker or druggable targets. This paper highlights the importance of viral and cellular miRNAs in EBOV infection and EVD.

Indexed as

Ebola virusMicroRNAsvirus diseases

Identifiers

PMID39184819
PMCPMC11344561

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.